Obesity Drug Pipeline Surges with 100+ Therapies from 80+ Companies in 2025
核心洞察
DelveInsight's 2025 pipeline report reveals a robust obesity (搜索) therapeutics landscape with over 80 companies developing more than 100 pipeline drugs across various clinical stages.
Major pharmaceutical companies including Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Carmot Therapeutics (搜索) are advancing multiple Phase II and III trials scheduled for February 2025.
Leading drug candidates include survodutide (Zealand Pharma/Boehringer Ingelheim), a dual GLP-1/glucagon receptor (搜索) agonist in Phase III trials, and CT-868 (Carmot Therapeutics (搜索)), a dual GLP-1/GIP receptor (搜索) modulator in Phase II development.
The obesity (搜索) therapeutics market is experiencing unprecedented growth, with a comprehensive pipeline analysis revealing over 80 companies actively developing more than 100 pipeline drugs for obesity treatment. According to DelveInsight's "Obesity Pipeline Insight 2025" report, the landscape demonstrates significant momentum across all clinical development stages.
Major Clinical Trials Launching in 2025
Several high-profile Phase II and III studies are scheduled to commence in February 2025, highlighting the industry's commitment to addressing the global obesity (搜索) epidemic. Eli Lilly and Company will evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults with obesity over an 89-week study period. Novo Nordisk A/S is advancing CagriSema, a novel combination therapy, in a comprehensive two-part study lasting three years total - a two-year main phase followed by a one-year extension phase.
Carmot Therapeutics (搜索) Inc. is conducting a randomized, double-blind, placebo-controlled Phase 2 study evaluating once-weekly CT-388 administered subcutaneously for 48 weeks in participants who are overweight or obese with Type 2 diabetes mellitus (搜索). Zomagen Biosciences Ltd (搜索) is investigating VTX3232 both as monotherapy and in combination with semaglutide in approximately 160 patients diagnosed with obesity (搜索).
Leading Pipeline Candidates
Survodutide: Dual-Mechanism Approach
Survodutide (BI 456906), developed by Zealand Pharma and advanced by Boehringer Ingelheim, represents a significant advancement in obesity (搜索) therapeutics. This long-acting glucagon/GLP-1 receptor (搜索) dual agonist for once-weekly subcutaneous administration activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity, targeting both obesity and nonalcoholic steatohepatitis (搜索) (NASH).
CT-868: Optimized Tolerability Profile
CT-868, developed by Carmot Therapeutics (搜索), is a dual GLP-1 and GIP receptor (搜索) modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor (搜索). The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. The dual agonist candidate was discovered using chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In Phase I trials, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals with a safe and generally well-tolerated profile.
Ecnoglutide: Novel GLP-1 Analog
Sciwind Biosciences (搜索) is developing Ecnoglutide (XW003), a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently in Phase III clinical trials for obesity (搜索) treatment, Ecnoglutide represents the potential of GLP-1 analogs as effective therapies in managing type 2 diabetes, obesity, and NASH.
DD01: Extended Half-Life Innovation
D&D Pharmatech (搜索)'s DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity (搜索) and liver fatty disease. In preclinical models, DD01 demonstrated greater efficacy than semaglutide, an approved GLP-1R receptor agonist, with effects persisting after cessation of treatment. The compound is currently in Phase I clinical trials investigating safety, tolerability, pharmacokinetics, and pharmacodynamics in overweight/obese subjects with type 2 diabetes mellitus (搜索) and nonalcoholic fatty liver disease (搜索).
Diverse Therapeutic Approaches
The obesity (搜索) pipeline encompasses various therapeutic modalities and administration routes. Products are categorized under multiple routes of administration including oral, parenteral, intravenous, subcutaneous, and topical delivery methods. The molecular diversity includes recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapy approaches.
Industry Landscape and Market Dynamics
Leading companies in the obesity (搜索) therapeutics space include Zealand Pharma, Sciwind Biosciences (搜索), Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, and Biolingus. Promising therapies in development include APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, and Bremelanotide.
The therapeutic assessment spans the complete development spectrum from discovery and preclinical stages through Phase I, II, and III clinical trials. Companies are pursuing both monotherapy and combination therapy approaches, with detailed analysis of collaborations, licensing agreements, and financing arrangements supporting future market advancement.
Specialized Treatment Approaches
Rhythm Pharmaceuticals is conducting a Phase 3 randomized, double-blind, placebo-controlled trial with multiple independent sub-studies of setmelanotide in patients with specific genetic variants including POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 gene variants in the melanocortin-4 receptor (搜索) pathway, addressing rare genetic forms of obesity (搜索).
The comprehensive pipeline analysis reveals a dynamic and rapidly evolving therapeutic landscape, with significant investment and innovation focused on addressing the global obesity (搜索) epidemic through diverse mechanistic approaches and novel drug delivery systems.